Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S2W-29090 · Session 2

What the additional cost to the NHS would be if donepezil, galantamine and rivastigmine were prescribed to those suffering from the mild fo…

Answered Asked by Euan Robson LD Lodged 16 Oct 2006

The question

To ask the Scottish Executive what the additional cost to the NHS would be if donepezil, galantamine and rivastigmine were prescribed to those suffering from the mild form of Alzheimer’s disease.

The answer

Answered by Lewis Macdonald on 10 Nov 2006 · 25 days after it was lodged, on time

Guidance issued by the NationalInstitute of Clinical Excellence in 2001, and endorsed by the then Health TechnologyBoard for Scotland, recommended the use of donepezil, galantamine and rivastigminefor patients suffering from mild to moderate dementia in Alzheimer’s disease. In2005-06, prescribing data on drugs dispensed in the community showed that £7,470,042was spent on the three drugs. Hospital prescribing data is not included. This costincludes the prescribing of the drugs to patients suffering from the mild form of the disease.
It is not possible to identifyfrom prescribing data the cost attributable to patients suffering from the mildform of the disease. The prescription form does not specify whether the drug isprescribed for a patient with mild or moderate disease. In addition, the costs varydepending on the drug prescribed and the required daily dose prescribed for eachindividual patient.

In the Official Report

No contribution in the Official Report cites S2W-29090 by reference.